Sanofi-aventis Establishes Research Collaboration with Harvard University

Sanofi-aventisSanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced a research collaboration with Harvard University. The goal of the collaboration is to advance knowledge in the area of human health through basic and applied research and to promote scientific exchange between Harvard University and sanofi-aventis. The focus of this collaboration is translational biomedical research in multiple therapeutic areas such as cancer, diabetes and inflammation.

"I'm delighted by the collaboration with sanofi-aventis, which joins together leaders in academic research and industry to more rapidly advance groundbreaking research from the lab to the clinic," said Steven E. Hyman MD, Provost of Harvard University. "This collaboration exemplifies Harvard's commitment to creatively partner with industry in ways that we hope will push the boundaries of translational science, and advance our mandate of serving the public interest by making the fruits of our research available to society."

The collaboration will support a number of activities over the term of the agreement through the granting of funding awards. Harvard University investigators will propose research projects across a wide range of areas. The funded projects will be selected by a Joint Scientific Steering Committee comprised of representatives of sanofi-aventis and Harvard, respectively. Projects will be awarded funding based on their scientific merit and potential to generate translational insight and value to biomedical research. These awards will provide Harvard researchers with focused, flexible and rapidly available financial support to enable research projects aimed at generating new knowledge and the development of innovative healthcare solutions in areas of high patient need. The collaboration provides sanofi-aventis the opportunity to develop diagnostic, therapeutic and prognostic applications of discoveries made.

As part of the relationship with Harvard, sanofi-aventis will periodically evaluate technologies that may be of interest which are identified by Harvard's Office of Technology Development. To further this exchange of ideas, sanofi-aventis will host an annual scientific forum that will bring together sanofi-aventis and university researchers to share knowledge and opinions on relevant scientific matters and to review progress of research projects funded through the collaboration.

"Our relationship with Harvard underscores sanofi-aventis' approach of leveraging our innovative internal resources while actively engaging a range of external partners to develop healthcare solutions," said Marc Cluzel, M.D., PhD, Executive Vice-President, Research & Development, sanofi-aventis. "We are hopeful that promoting open scientific exchange between Harvard's leading biological researchers and sanofi-aventis' drug development environment will drive significant healthcare advances. We are very excited about this collaboration."

About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, please visit www.sanofi-aventis.com.

About Harvard University's Office of Technology Development
The Harvard Office of Technology Development (OTD) is responsible for all activities pertaining to the evaluation, patenting and licensing of new inventions and discoveries made at Harvard University and Harvard Medical School. OTD also serves to further the development of Harvard technologies through the establishment of sponsored research collaborations with industry. OTD’s mission is to promote the public good by fostering innovation and translating new inventions made at Harvard into useful products available and beneficial to society.

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...